|
Is blood transfusion safe during the COVID-19 pandemic?
|
Sep 2020
|
Future Science OA
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?
|
Sep 2020
|
Expert Review of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Novel therapeutic choices in immune aplastic anemia
|
Sep 2020
|
F1000Research
|
aplastic anemia
|
|
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
|
Sep 2020
|
PloS One
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
|
Sep 2020
|
Leukemia & Lymphoma
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
The Problem of TP53-Mutant MDS/AML
|
Sep 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
New Approaches for Anemia in MDS
|
Sep 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Pitfalls in Assessing Response to Treatment in MDS
|
Sep 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index
|
Sep 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
|
Aug 2020
|
Journal of Patient-Reported Outcomes
|
myelodysplastic syndromes (MDS)
|
